Hospital
Miami Beach Healthcare Group, LTD.
Miami Beach Healthcare Group, LTD. was paid $6.05M by Medicaid between Jan 2018 and Dec 2024, across 153 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoMIAMI BEACH HEALTHCARE GROUP, LTD.
AVENTURA, FL 33180
AVENTURA, FL 33180
33aNPI1407801673assigned 05/24/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.05M
24GClaims373,557
24DCodes billed153
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#73 of 163
Median peer was paid$4.77M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,994 | $457K | |
| 2019 | 79,537 | $726K | |
| 2020 | 63,490 | $898K | |
| 2021 | 72,066 | $1.26M | |
| 2022 | 75,409 | $1.55M | |
| 2023 | 29,696 | $728K | |
| 2024incomplete | 12,365 | $427K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 19,678 | 16,543 | $1.19M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 16,167 | 14,352 | $1.04M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.0% | 9,333 | 7,005 | $545K |
| 80053 | Comprehensive metabolic panel | 8.6% | 25,108 | 19,017 | $522K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.5% | 3,226 | 2,742 | $394K |
| G0378 | Hospital observation service, per hour | 4.8% | 10,419 | 5,434 | $288K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 3,794 | 3,046 | $233K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 2,675 | 2,440 | $174K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.8% | 1,310 | 1,059 | $169K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.5% | 1,220 | 1,012 | $150K |
| A9270 | Non-covered item or service | 2.2% | 19,255 | 2,859 | $133K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.8% | 1,505 | 1,323 | $109K |
141 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 1,171 | $85K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.3% | 1,617 | $78K |
| 85027 | <1% | 31,126 | $52K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,145 | $48K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,355 | $45K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,345 | $44K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,480 | $31K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,343 | $28K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,590 | $26K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 564 | $24K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,302 | $24K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,534 | $24K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,067 | $24K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,232 | $24K |
| 81025 | <1% | 5,631 | $22K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,813 | $21K |
| 86850 | <1% | 2,338 | $20K | |
| 87070 | <1% | 1,587 | $20K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,968 | $19K |
| 70496 | <1% | 129 | $18K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 716 | $18K |
| 81001 | <1% | 8,586 | $16K | |
| 84484 | <1% | 12,174 | $15K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,929 | $14K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 4,541 | $14K |
| 85610 | <1% | 5,722 | $13K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,156 | $12K |
| 80047 | <1% | 443 | $12K | |
| 87275 | <1% | 3,133 | $11K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,216 | $11K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,056 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,166 | $11K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 922 | $11K |
| 85730 | <1% | 5,040 | $11K | |
| 84702 | <1% | 1,758 | $10K | |
| 87088 | <1% | 3,117 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,272 | $9K |
| 73564 | <1% | 896 | $9K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 804 | $9K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 431 | $8K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,783 | $8K |
| 86900 | <1% | 3,109 | $7K | |
| 76801 | <1% | 782 | $7K | |
| 87040 | <1% | 2,223 | $7K | |
| 87077 | <1% | 1,350 | $6K | |
| 81003 | <1% | 3,591 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 375 | $6K |
| 93970 | <1% | 587 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,330 | $6K |
| 70486 | <1% | 127 | $6K | |
| 73630 | <1% | 715 | $6K | |
| 76830 | Ultrasound, transvaginal | <1% | 403 | $6K |
| 73610 | <1% | 512 | $6K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 515 | $5K |
| 83735 | <1% | 4,709 | $5K | |
| 83880 | <1% | 3,257 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 162 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,002 | $4K |
| 83690 | <1% | 5,946 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 253 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,905 | $4K |
| 82553 | <1% | 1,141 | $4K | |
| 82550 | <1% | 3,400 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,285 | $3K |
| 71250 | <1% | 141 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 243 | $3K |
| 73130 | <1% | 391 | $3K | |
| 86901 | <1% | 3,064 | $3K | |
| 97162 | <1% | 291 | $3K | |
| 84100 | <1% | 3,157 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 269 | $3K |
| 83605 | <1% | 3,133 | $2K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,034 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $2K |
| 72131 | <1% | 86 | $2K | |
| 87186 | <1% | 1,089 | $2K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 942 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,544 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 567 | $2K |
| 73030 | <1% | 465 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 150 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 110 | $1K |
| 87205 | <1% | 688 | $1K | |
| 74018 | <1% | 89 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 701 | $1K |
| C1769 | Guide wire | <1% | 125 | $1K |
| 93971 | <1% | 145 | $1K | |
| 73110 | <1% | 185 | $1K | |
| 85379 | <1% | 1,594 | $1K | |
| 80061 | Lipid panel | <1% | 1,022 | $862.87 |
| 84703 | <1% | 2,003 | $794.41 | |
| 86140 | <1% | 1,264 | $732.83 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 617 | $690.97 |
| 87276 | <1% | 3,133 | $555.95 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 419 | $457.75 |
| 85651 | <1% | 645 | $391.29 | |
| 90714 | <1% | 244 | $382.35 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 568 | $368.06 |
| 73080 | <1% | 30 | $367.75 | |
| 73590 | <1% | 42 | $364.66 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 66 | $345.13 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | <1% | 366 | $289.31 |
| 70498 | <1% | 90 | $248.49 | |
| 72100 | <1% | 27 | $211.81 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 66 | $202.93 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 419 | $175.04 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,476 | $132.60 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 51 | $119.20 |
| 84439 | <1% | 33 | $114.21 | |
| 87400 | <1% | 42 | $90.34 | |
| 86923 | <1% | 128 | $88.41 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 213 | $81.45 |
| 97116 | <1% | 100 | $41.76 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 34 | $32.68 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 147 | $24.35 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 183 | $16.89 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 406 | $16.89 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 565 | $5.53 |
| 80076 | <1% | 56 | $3.06 | |
| 82247 | 0% | 14 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 32 | $0.00 |
| 84450 | 0% | 15 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 45 | $0.00 |
| 82009 | 0% | 20 | $0.00 | |
| 87210 | 0% | 14 | $0.00 | |
| 83540 | 0% | 49 | $0.00 | |
| 84460 | 0% | 14 | $0.00 | |
| 87075 | 0% | 29 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 13 | $0.00 |
| 84155 | 0% | 14 | $0.00 | |
| 76376 | 0% | 12 | $0.00 | |
| 83615 | 0% | 416 | $0.00 | |
| 83550 | 0% | 49 | $0.00 | |
| 96376 | 0% | 135 | $0.00 | |
| 82077 | 0% | 87 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 100 | $0.00 |
| 72170 | 0% | 162 | $0.00 | |
| 73090 | 0% | 16 | $0.00 | |
| 82040 | 0% | 14 | $0.00 | |
| 73502 | 0% | 54 | $0.00 | |
| 84075 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPANIRY, DAVID (CFO)